« Return to News | CROs/Service Providers | Drug Sponsors

inVentiv Health to acquire SDI businesses from IMS Health

Friday, January 20, 2012 02:53 PM

Burlington, Mass.-based inVentiv Health will acquire certain promotional and medical audit businesses of SDI Health, which IMS Health has committed to divest in connection with obtaining regulatory approval of its acquisition of SDI.  Financial terms were not disclosed.

The business will be incorporated into the offerings of Campbell Alliance, an inVentiv Health company and a management consulting firm specializing in the pharmaceutical and biotech industry. Campbell Alliance will add a range of promotional and medical audits based on proprietary research that leading healthcare companies use to better understand their markets and make more highly informed business decisions.

"This is an important step in boosting inVentiv's capabilities in market research and analytics," said Paul Meister, CEO of inVentiv Health. "These additional capabilities allow us to provide a more comprehensive offering that augments our clients' business decision-making."

The transaction is expected to close in February.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.